News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Muscle damage risk from cholesterol-lowering drug rare

16 May 2014

Serious muscle damage risk from widely used cholesterol lowering drug very low in general population: Otago research

New Zealanders taking a higher dose of simvastatin, one of the statin drugs used to prevent heart attacks and strokes, have a greater risk of rhabdomyolysis than people taking a lower dose according to new University of Otago research. However the condition, in which breakdown of muscle tissue can lead to acute kidney failure, is still very rare in both groups.

In a new study published in the journal International Journal of Cardiology, the researchers found that people taking 40mg of simvastatin daily were about five times as likely to develop rhabdomyolysis when compared with people taking 20mg daily.

In absolute terms, the risks were about 11 per 100,000 person-years in people taking 40mg simvastatin and 2 per 100,000 person-years in those taking 20mg.

Study lead investigator Dr Lianne Parkin says recent meta-analyses have clearly shown that the benefits of statins in preventing major cardiovascular events far outweigh any serious adverse effects associated with their use.

“However, these meta-analyses were based on highly selected participants in randomised controlled trials and there was very little information about the risk of rhabdomyolysis in people taking the doses of simvastatin that are recommended for use in New Zealand,” Dr Parkin says.

“While previous research has found a greater risk of serious muscle damage in people taking higher doses of statins, our study is the largest investigation to date of rhabdomyolysis in a general population of simvastatin users and the first to provide separate estimates of risk for 40mg and 20mg simvastatin.”

The researchers used routinely collected health and prescription medicine data to conduct a study based on 313,552 people of all ages who were dispensed simvastatin at any time between 2005 and 2009. Other factors, including age, sex, medical conditions, and other prescription drugs, were taken into account in the analyses.

“Statins are one of the most widely used classes of drugs,” says Dr Parkin, “and it is reassuring to have found a very low risk of rhabdomyolysis in New Zealanders using simvastatin. The greater risk associated with the use of 40mg simvastatin is one of several factors which patients and their doctors might consider when discussing the balance of benefits and risks of cholesterol-lowering treatment, and the most appropriate dose and type of statin to be used.”

The research was funded by Medsafe and the Health Research Council of New Zealand.

Publication details:
Parkin L, Paul C, Herbison GP. Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Review: Singin’ In The Rain

Singin’ in the Rain , the wet and wonderful musical production all the way from London’s West End, officially opened at St. James Theatre in Wellington. More>>

Francis Cook: Gallipoli: The Scale Of Our War – First Look

Te Papa today allowed media access to their new exhibition Gallipoli: The Scale of Our War . The exhibition was curated with help from Weta Workshop to deliver an immersive, realistic and even disorienting experience. More>>

ALSO:

Bats Theatre: Letters From The Front Brings ANZAC Letters Alive

Inspired by centenary commemorations, improv troupe Best on Tap is producing a show based on real-life letters sent to and from New Zealand soldiers in the First World War. More>>

ALSO:

Publishing: Unity Books On Plan To Close Te Papa Press

Unity Books is alarmed that Te Papa is proposing to suspend publishing by Te Papa Press for 4 or 5 years. Te Papa Press has proven time and time again that it has both award and bestseller capability and fulfils its kaupapa. More>>

ALSO:

Cinema: ‘The Desk’ Featuring Paul Henry To Have NZ Debut

The Documentary Edge Festival is thrilled to announce The Desk as a late entry to its 2015 Programme. The film, featuring local broadcaster Paul Henry, will have its international premiere on May 21 at 10pm at Q Theatre (book now at qtheatre.co.nz) with limited screenings also on offer in Wellington and Auckland. More>>

ALSO:

Art: Considering Feminisms In Aotearoa New Zealand: Two Projects

Feminism is something that has changed our lives. Recently, the activist Marilyn Waring reviewed the impact of feminism in Aotearoa New Zealand and reminded us that just 40 years ago banks wouldn’t lend women money without the guarantee of a man, ... More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news